Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline cancer treatment clearance

GlaxoSmithKline cancer treatment clearance

2nd February 2006

GlaxoSmithKline (GSK) has received European clearance for the cancer treatment Hycamtin (topotecan powder for concentrate for solution for infusion).

The decision by the European Commission to give marketing authorisation to Hycamtin makes it the first drug in Europe indicated for treatment of small cell lung cancer (SCLC).

Already used for the treatment of relapsed ovarian cancer, it is hoped it will offer extended survival benefit and enhance patient quality of life.

Dr Mary O’Brien, head of the lung cancer unit at the Royal Marsden NHS foundation trust, said: “The oral form of Hycamtin has shown promising and unexpected results in improving symptoms and lengthening the life of patients with relapsed SCLC, a disease that is traditionally associated with a grave outlook for patients

“This approval of intravenous Hycamtin will now provide physicians and our patients an important new treatment option in SCLC.”

The decision follows the positive opinion from the European Medicines Agency ‘s (EMEA) Committee for Medicinal Products for Human Use (CHMP) for GSK’s quarterly intravenous injection of the osteoporosis medication Bonviva (ibandronic acid).

track© Adfero Ltd

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.